Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BLAZE PIZZA TURNS UP THE PROTEIN WITH NEW LIMITED-TIME “PROTEIN-ZZA,” MEETING GROWING DEMAND FOR GLP-1-FRIENDLY OPTIONS
-
MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI
-
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced access to Novo Nordisk’s newly...
-
Kailera Therapeutics today announced the appointment of Doug Pagán as its Chief Financial Officer.
-
Analysis examines best tirzepatide access pathways for 2026 including FDA regulatory changes, insurance coverage shifts, and cash-pay options.
-
Independent analysis of best weight loss patches and GLP-1 patch products as FDA approves once-daily Wegovy pill for chronic weight management.
-
Kailera Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference in January.
-
SkinnyRx offers compounded semaglutide in 3 forms starting at $199/month through licensed providers as New Year weight loss demand approaches.
-
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated...
-
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, today introduced a new, fully integrated...